Curio Bioscience Pen Partnership with DNAnexus, Simplifying Data Analysis in Spatial Transcriptomics
Two Palo Alto, CA, companies have agreed to collaborate in a partnership announced on 21 February 2024.
DNAnexus is the provider of Precision Health Data Cloud, a service that aims to manage and analyse precision data in drug discovery pipelines. And Curio Bioscience is an American developer of spatial tools to map the whole transcriptome in high resolution.
The collaboration will see Precision Health Data Cloud integrated into Curio’s Seeker Spatial Mapping Kit offering. Curio’s customers will be able to access the data analysis environment to process data sets obtained using the Seeker platform.
RELATED:
- Spatial and Single Cell Transcriptomics Uncovers Mechanisms for Ischemic Stroke Recovery
- Spatial Transcriptomics Technologies: Current Trends and Analysis
- Spatial Revolution: Harnessing Spatial Technologies In The Clinic For A Healthier Tomorrow
The Curio Seeker Spatial Mapping Kit allows the user to map the entire transcriptome spatially, and in high resolution. Next generation sequencing techniques allow Seeker to generate spatial molecular maps of selected tissues which include the location of RNAs.
Curio CTO and Co-founder, Christina Fan said: “The Precision Health Data Cloud streamlines the process for biologists by making primary data analysis easy to initiate without support from bioinformaticians or investment in computing infrastructure.”
By combining their technologies, both companies hope to accelerate research and gain further insight into selected tissues’ molecular makeup.
“This collaboration with DNAnexus provides our customers with a fully integrated, easy-to-use, and scalable cloud-based environment for accessing and analyzing the rich, whole transcriptome, and high resolution spatial data sets generated by the Curio Seeker workflow,” commented Fan.
DNAnexus handles over 105 petabytes of data for a network of various pharma and healthcare organisations. Curio is now the most recent of many companies that have agreed to access the bioinformatics platform.